Study guide

5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

Key Takeaways Explain This Topic AI

Carbon monoxide poisoning gives a normal PaO2 with low measured oxygen saturation on co-oximetry, while pulse oximetry reads falsely normal.

Ethylene glycol and methanol both raise the osmolar gap early and the anion gap late; fomepizole or ethanol blocks alcohol dehydrogenase, and methanol specifically causes optic neuropathy.

Organophosphate poisoning produces the cholinergic DUMBELS picture and is treated with high-dose atropine titrated to secretions plus pralidoxime.

Last updated: September 2026

Clinical Toxidromes and Emergency Antidotes

A toxidrome is a constellation of physical signs and physiological parameters characteristic of a specific class of toxin:

Toxidrome Vital Signs Pupils Skin / Mucosa Mental Status & Key Signs Common Causative Agents Specific Antidote / Management

Opioid • Bradycardia; • Hypotension; • Bradypnoea / Apnoea ; • Hypothermia Pinpoint (Miosis) Normal / Cool • Stupor / Coma; • Reduced bowel sounds; • Respiratory depression Morphine, Diamorphine, Methadone, Fentanyl, Oxycodone Naloxone ; • Initial dose 400 ug IV; titrate to restore spontaneous RR >= 10/min (not full arousal).

Anticholinergic (Antimuscarinic) • Tachycardia; • Hypertension; • Hyperthermia Dilated (Mydriasis) Dry, flushed skin ; • Dry mucous membranes • Agitated delirium; • Visual hallucinations; • Urinary retention; • Absent bowel sounds Tricyclics, Atropine, Hyoscine, Diphenhydramine, Promethazine • Supportive care.; • Urinary catheterisation.; • Benzodiazepines for agitation.; • Physostigmine (rarely used) .

Cholinergic • Bradycardia; • Bronchorrhoea; • Bronchospasm Pinpoint (Miosis) Profusely diaphoretic ; • Excessive salivation • Fasciculations, weakness; • SLUDGE / DUMBELS (Diarrhoea, Urination, Miosis, Bronchorrhoea, Emesis, Lacrimation, Salivation) Organophosphates, Carbamate insecticides, Nerve agents (Novichok, Sarin) Atropine (2 mg IV boluses, double every 5 min until pulmonary secretions dry).; Pralidoxime (oxime cholinesterase reactivator).

Sympathomimetic • Severe Tachycardia; • Severe Hypertension; • Hyperthermia Dilated (Mydriasis) Profusely diaphoretic (Sweaty) • Extreme agitation, paranoia; • Hyperreflexia, tremor; • Seizures, hyperthermia Cocaine, Amphetamines, MDMA (Ecstasy), Methamphetamine • Benzodiazepines (IV diazepam).; • Active cooling.; • Avoid pure beta-blockers (unopposed alpha-vasoconstriction).

Sedative / Hypnotic • Mild bradycardia; • Mild hypotension; • Normal/depressed RR Normal / Variable Normal • Lethargy, slurred speech; • Ataxia, stupor, coma; • Normal pupillary reflexes Benzodiazepines (diazepam), Z-drugs (zopiclone), Barbiturates • Airway protection & supportive care.; • Flumazenil (Generally avoided: risks precipitating intractable seizures).

Tip

Exam Distinction: Anticholinergic vs Sympathomimetic :

Both toxidromes present with tachycardia, hypertension, hyperthermia, and dilated pupils (mydriasis). The decisive differentiating clinical sign is the skin : anticholinergic toxicity produces bone-dry skin and dry axillae ("dry as a bone"), whereas sympathomimetic toxicity produces profuse diaphoresis (drenching sweat) .

  • Carbon Monoxide and Cyanide Toxicity
  • 1. Carbon Monoxide (CO)

Pathophysiology : Carbon monoxide binds to haemoglobin with 200 to 250 times greater affinity than oxygen, forming carboxyhaemoglobin (COHb) . COHb cannot bind oxygen, halving oxygen-carrying capacity. Furthermore, CO binding shifts the oxyhaemoglobin dissociation curve sharply to the left (Haldane effect) , locking remaining oxygen onto haemoglobin and preventing its release into ischaemic tissues. CO also inhibits mitochondrial cytochrome oxidase.

Diagnostic Pitfall : Standard bedside pulse oximetry (SpO2) is falsely normal (e.g., 99–100%) because standard dual-wavelength pulse oximeters cannot distinguish between oxyhaemoglobin and carboxyhaemoglobin. Arterial or venous blood gas with dedicated co-oximetry is mandatory to quantify COHb percentage.

Clinical Presentation : Headache (earliest symptom), nausea, malaise, dizziness, confusion, ataxia, angina, cardiac arrest. The textbook "cherry-red skin" is an exceptionally rare, post-mortem sign.

Management :

Remove from source; immediately administer 100% normobaric oxygen via non-rebreather reservoir mask (reduces COHb half-life from 320 minutes on room air down to 80 minutes).

Hyperbaric Oxygen (HBO) : Delivers 100% O2 at 2.5 to 3.0 atmospheres (reducing t1/2 to 20 minutes). Indications include: COHb > 25% (or > 15–20% in pregnancy), loss of consciousness, neurological deficits, myocardial ischaemia, or severe refractory acidosis.

2. Cyanide Toxicity

Pathophysiology : Hydrogen cyanide gas is released during the combustion of synthetic plastics, wool, and polyurethane foams in domestic house fires (often co-existing with CO poisoning). Cyanide binds with high affinity to ferric (Fe3+) iron in cytochrome c oxidase (Complex IV) of the mitochondrial electron transport chain, arresting aerobic cellular respiration. Cells switch entirely to anaerobic metabolism, producing massive lactic acidosis .

Signature Laboratory Clue : A patient pulled from a house fire with profound metabolic acidosis and an extraordinarily elevated serum lactate (> 8–10 mmol/L) despite adequate oxygenation. Venous blood remains bright red with a high mixed venous oxygen saturation (SvO2 > 90%) because peripheral tissues are incapable of extracting oxygen.

Specific Antidote : Intravenous Hydroxocobalamin (Cyanokit) . Hydroxocobalamin actively chelates cyanide, forming non-toxic cyanocobalamin (Vitamin B12) , which is safely excreted in urine (turning urine dark red/purple). Avoid sodium nitrite in smoke inhalation because inducing methaemoglobinaemia will further impair oxygen-carrying capacity in the presence of co-existing carboxyhaemoglobin.

Toxic Alcohols: Ethylene Glycol vs Methanol

Ethylene glycol (automobile antifreeze) and methanol (windscreen washer fluid, methylated spirits, bootleg alcohol) are parent alcohols that are relatively non-toxic themselves; however, they are metabolised by hepatic alcohol dehydrogenase (ADH) into devastatingly toxic organic acids. +-----------------------------------------------------------------------------------------+

  • | Toxic Alcohol Metabolic Cascades |
  • +-----------------------------------------------------------------------------------------+
  • | ETHYLENE GLYCOL ---> | Alcohol Dehydrogenase | ---> Glycolic Acid ---> Oxalic Acid |
  • | | |
  • | Calcium Oxalate Crystal Precipitation |
  • | (Renal Tubular Necrosis & Hypocalcaemia) |
  • | |
  • | METHANOL ----------> | Alcohol Dehydrogenase | ---> Formaldehyde ---> Formic Acid |
  • | | |
  • | Optic Nerve Necrosis ("Snowstorm" Vision) |
  • | & Basal Ganglia / Putaminal Necrosis |
  • +-----------------------------------------------------------------------------------------+
  • Laboratory Trajectory: The Shifting Gap Phenomenon

Early Phase (0–6 hours) : Parent alcohol circulates unmetabolised. High concentration of low-molecular-weight molecules produces an elevated Serum Osmolar Gap (> 10 mOsm/kg), while the anion gap remains normal: Calculated Osmolarity = 2 x [Na+] + [Glucose] + [Urea] (all in mmol/L)

Osmolar Gap = Measured Osmolality (by freezing-point depression) - Calculated Osmolarity

Late Phase (> 12 hours) : As alcohol dehydrogenase oxidises the parent alcohols, the osmolar gap steadily closes, and an enormous High Anion Gap Metabolic Acidosis (HAGMA) opens up due to circulating glycolate/oxalate or formate.

Key Clinical Distinctions

Ethylene Glycol : Metabolised to oxalic acid , which precipitates with calcium to form needle- or envelope-shaped calcium oxalate crystals in the renal tubules, producing acute tubular necrosis, flank pain, microscopic haematuria, and marked hypocalcaemia (tetany, prolonged QT interval). Urine exhibits bright apple-green fluorescence under a Wood's UV lamp (due to fluorescein added to commercial antifreeze).

Methanol : Metabolised to formic acid , which specifically poisons mitochondrial cytochrome oxidase in the retina and optic nerve. Patients describe visual blurring, visual loss, or visual hallucinations classically described as "standing in a snowstorm" , with dilated unreactive pupils and optic disc hyperaemia on fundoscopy. Bilateral necrosis of the putamen (basal ganglia) is seen on neuroimaging.

Management of Toxic Alcohols

Block Alcohol Dehydrogenase (ADH) :

Fomepizole (4-methylpyrazole) : Competitive inhibitor of alcohol dehydrogenase with an affinity 8,000-fold higher than ethanol. First-line agent; administered as an IV bolus (15 mg/kg) followed by scheduled dosing.

Intravenous Ethanol Infusion : Second-line if fomepizole is unavailable. Competing substrate for ADH; titrated to achieve a target blood ethanol concentration of 100–150 mg/dL (22–33 mmol/L).

Emergency Haemodialysis : Rapidly eliminates parent alcohols and toxic acid metabolites while correcting severe acidosis. Absolute indications include: severe metabolic acidosis (pH < 7.25), visual symptoms (methanol), acute renal failure (ethylene glycol), or serum concentration > 50 mg/dL (> 8 mmol/L).

Loading diagram... Toxic Alcohol Emergency Diagnostic & Therapeutic Pathway